Diagnostic labels alone provide limited guidance for assessment or treatment of sleep disorders in children with neurodevelopmental disorders; a diagnosis-informed, phenotype-directed framework is proposed.
The paper reviews evidence that sleep disorders are highly prevalent in children with neurodevelopmental disorders (NDDs) and that diagnostic labels are insufficient for guiding care. It proposes a framework that integrates diagnosis-informed risk recognition with phenotype-directed assessment, focusing on sleep phenotypes such as insomnia, circadian dysregulation, sleep-disordered breathing, movement disorders, hypersomnolence, and parasomnias. Melatonin has the strongest pharmacological evidence, particularly for insomnia in ASD and selected neurogenetic conditions.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Diagnostic labels alone provide limited guidance for assessment or treatment of sleep disorders in children with neurodevelopmental disorders; a diagnosis-informed, phenotype-directed framework is proposed. The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Diagnostic labels alone provide limited guidance for assessment or treatment of sleep disorders in children with neurodevelopmental disorders; a diagnosis-informed, phenotype-directed framework is proposed.
This conclusion is most relevant to: Children with neurodevelopmental disorders (autism, ADHD, intellectual disability, genetic syndromes).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Sleep in Children with Neurodevelopmental Disorders: From Diagnostic Labels to Phenotype-directed Care. (Current neurology and neuroscience reports, 2026) —
How It Works
The proposed biological pathway:
- ▸Identify neurodevelopmental diagnosis to recognize syndrome-specific risks
- ▸Assess dominant sleep phenotype (e.g., insomnia, circadian dysregulation)
- ▸Evaluate contributing medical and environmental factors
- ▸Guide investigation and treatment based on phenotype and functional consequences
Who Might Benefit
Evidence fit by population:
- ▸Children with neurodevelopmental disorders (autism, ADHD, intellectual disability, genetic syndromes)
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Review article, not a primary study; no quantitative effect sizes
- ▸Evidence for many NDD populations and sedating agents remains limited
- ▸Calls for better trials including children with severe disability and rare NDDs
Frequently Asked Questions
What is the main recommendation for managing sleep disorders in children with neurodevelopmental disorders?▼
The main recommendation is to use a diagnosis-informed, phenotype-directed framework, where the neurodevelopmental diagnosis identifies syndrome-specific risks and surveillance needs, while the dominant sleep phenotype and contributing factors guide investigation and treatment.
Which pharmacological treatment has the strongest evidence for sleep disorders in this population?▼
Melatonin has the strongest pharmacological evidence, particularly for insomnia in autism spectrum disorder (ASD) and selected neurogenetic conditions.
What are the clinically relevant sleep phenotypes mentioned in the paper?▼
The clinically relevant phenotypes include insomnia and circadian dysregulation, sleep-disordered breathing, sleep-related movement disorders, hypersomnolence, and parasomnias.
Why are diagnostic labels alone insufficient for managing sleep disorders in children with NDDs?▼
Diagnostic labels alone are insufficient because sleep disturbance is heterogeneous within and across different NDDs, and the same diagnosis can present with different sleep phenotypes, requiring individualized assessment and treatment.
References
- 1.Bruni O, Breda M, Mammarella V, Polese D, Mogavero MP, Lanza G, Ferri R. “Sleep in Children with Neurodevelopmental Disorders: From Diagnostic Labels to Phenotype-directed Care..” Current neurology and neuroscience reports, 2026. PMID: 42635877 DOI: 10.1007/s11910-026-01513-2